Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kexun Zhou

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
BMC Gastroenterology|August 17, 2022
Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature reviewKe Cheng, Xia Liu, Ye Chen, et al.
Molecular Cancer Therapeutics|October 17, 2024
Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and ProspectsWanting Lei, Kexun Zhou, Ye Lei, et al.
Molecular Biomedicine|January 9, 2025
Cancer vaccines: platforms and current progressWanting Lei, Kexun Zhou, Ye Lei, et al.
Cancer Management and Research|December 19, 2019
Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal CancerLiangliang Bai, Pengfei Zhang, Kexun Zhou, et al.
NPJ Biofilms and Microbiomes|July 27, 2025
Gut microbiota shapes cancer immunotherapy responsesWanting Lei, Kexun Zhou, Ye Lei, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 8, 2021
Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United statesFeng Wen, Hanrui Zheng, Pengfei Zhang, et al.
Bioresource Technology|February 13, 2016
Using thermal balance model to determine optimal reactor volume and insulation material needed in a laboratory-scale composting reactorYongjiang Wang, Li Pang, Xinyu Liu, et al.
Oral Oncology|May 20, 2020
Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspectiveKexun Zhou, Yunzhu Li, Weiting Liao, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancerKexun Zhou, Jing Zhou, Jiaxing Huang, et al.
Frontiers in Cell and Developmental Biology|March 4, 2022
Integratively Genomic Analysis Reveals the Prognostic and Immunological Characteristics of Pyroptosis and Ferroptosis in Pancreatic Cancer for Precision ImmunotherapyTing Yu, Huaicheng Tan, Chunhua Liu, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
BMC Gastroenterology|August 17, 2022
Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature reviewKe Cheng, Xia Liu, Ye Chen, et al.
Molecular Cancer Therapeutics|October 17, 2024
Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and ProspectsWanting Lei, Kexun Zhou, Ye Lei, et al.
Molecular Biomedicine|January 9, 2025
Cancer vaccines: platforms and current progressWanting Lei, Kexun Zhou, Ye Lei, et al.
Cancer Management and Research|December 19, 2019
Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal CancerLiangliang Bai, Pengfei Zhang, Kexun Zhou, et al.
NPJ Biofilms and Microbiomes|July 27, 2025
Gut microbiota shapes cancer immunotherapy responsesWanting Lei, Kexun Zhou, Ye Lei, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 8, 2021
Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United statesFeng Wen, Hanrui Zheng, Pengfei Zhang, et al.
Bioresource Technology|February 13, 2016
Using thermal balance model to determine optimal reactor volume and insulation material needed in a laboratory-scale composting reactorYongjiang Wang, Li Pang, Xinyu Liu, et al.
Oral Oncology|May 20, 2020
Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspectiveKexun Zhou, Yunzhu Li, Weiting Liao, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancerKexun Zhou, Jing Zhou, Jiaxing Huang, et al.
Frontiers in Cell and Developmental Biology|March 4, 2022
Integratively Genomic Analysis Reveals the Prognostic and Immunological Characteristics of Pyroptosis and Ferroptosis in Pancreatic Cancer for Precision ImmunotherapyTing Yu, Huaicheng Tan, Chunhua Liu, et al.
Pageof 4